Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of administering
Herceptin in combination with Taxol (paclitaxel) in the treatment of women with
HER2-positive, early stage breast cancer prior to surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Harold J. Burstein, MD, PhD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Bristol-Myers Squibb Dana-Farber Cancer Institute Genentech, Inc. Harvard Vanguard Medical Associates Massachusetts General Hospital